Revenue for FY26 is expected to reach £1.4 million, driven by expanded NHS and international adoption of MT-RNR1 and CYP2C19 tests. Strategic collaborations, regulatory progress, and a strong cash position support further growth and clinical integration.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.